Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Understanding the cause of TKI resistance to improve management strategies in CML

Jeffrey Lipton • 26 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Jeffrey Lipton, PhD, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, discusses management strategies for patients with chronic myeloid leukemia (CML) who are resistant to tyrosine kinase inhibitors (TKI), highlighting the importance of defining the cause of resistance to better tailor CML treatment to each patient. Prof. Lipton also emphasizes that increasing compliance is key to raising the efficacy of TKI therapy. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jeffrey Lipton

6:22
Efficacy & tolerability of available TKI therapies in CML & managing TKI resistance
Jeffrey Lipton • 26 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals